A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (BERENICE)
A Multicenter, Multinational, Phase II Study to Evaluate Perjeta in Combination With Herceptin and Standard Neoadjuvant Anthracycline-Based Chemotherapy in Patients With HER2-Positive, Locally Advanced, Inflammatory, or Early-Stage Breast Cancer
Sponsor: Hoffmann-La Roche
This PHASE2 trial investigates Breast Cancer and is currently completed. Hoffmann-La Roche leads this study, which shows 22 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
22 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE2
▶ Show 17 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE2
-
May 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
-
Feb 2020 — May 2020 [monthly]
Active Not Recruiting PHASE2
-
Nov 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
-
Sep 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
-
May 2019 — Sep 2019 [monthly]
Active Not Recruiting PHASE2
-
Feb 2019 — May 2019 [monthly]
Active Not Recruiting PHASE2
-
Dec 2018 — Feb 2019 [monthly]
Active Not Recruiting PHASE2
-
Sep 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Dec 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE2
-
Aug 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE2
-
May 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Amarillo, United States , Badalona, Spain , Bagno a Ripoli, Italy , Barrie, Canada , Bath, United Kingdom , Bellingham, United States , Bergen, Norway , Bialystok, Poland , Bournemouth, United Kingdom and 64 more locations